470 results on '"Solomon, Scott"'
Search Results
2. Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis
3. Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function
4. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure
5. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
6. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction
7. Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis
8. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials JACC Review Topic of the Week
9. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
10. Kidney Function and Outcomes in Patients Hospitalized With Heart Failure
11. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
12. Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction
13. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure
14. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis
15. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure
16. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction
17. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction
18. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
19. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
20. Association of Left Atrial Structure and Function With Heart Failure in Older Adults
21. Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure
22. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
23. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF
24. Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week
25. Incidence and Outcomes of Pneumonia in Patients With Heart Failure
26. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function
27. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
28. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction
29. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial
30. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF
31. Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women
32. Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk
33. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure
34. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure
35. Declining Lung Function and Cardiovascular Risk: The ARIC Study
36. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
37. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory
38. Right Ventricular Function and Coupling to Pulmonary Circulation in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial
39. Virtual Care Team Guided Management of Patients With Heart Failure During Hospitalization
40. MISSENSE GENETIC VARIATION OF ICAM1 AND INCIDENT HEART FAILURE: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
41. WHY MEASURE NT-PROBNP SERIALLY IN CHRONIC HEART FAILURE? MECHANISTIC ASSOCIATIONS OF NATRIURETIC PEPTIDE SLOPE FOLLOWING INITIATION OF SACUBITRIL/VALSARTAN
42. AFICAMTEN IN PATIENTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (REDWOOD-HCM COHORT 4)
43. GEOGRAPHICAL VARIATION IN PATIENT CHARACTERISTICS AND OUTCOMES IN HFPEF
44. THE EFFECT OF DAPAGLIFLOZIN ON INSULIN INITIATION OR INTENSIFICATION IN PATIENTS IN HEART FAILURE AND DIABETES: A POOLED ANALYSIS OF DAPA-HF AND DELIVER
45. PREDICTING STROKE IN HEART FAILURE AND PRESERVED EJECTION FRACTION WITHOUT ATRIAL FIBRILLATION
46. GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL
47. Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction
48. RED CELL DISTRIBUTION WIDTH IS AN INDEPENDENT PREDICTOR OF OUTCOMES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: AN ANALYSIS OF THE PARAGON-HF TRIAL
49. CA125 IN PATIENTS WITH HFREF AND THE EFFECT OF DAPAGLIFLOZIN: INSIGHTS FROM DAPA-HF
50. LONG-TERM EFFICACY AND SAFETY OF AFICAMTEN IN PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.